semaglutide + insulin glargine

Semaglutide + insulin glargine is a combination therapy involving two pharmaceutical agents for the management of type 2 diabetes mellitus. **Semaglutide** is a glucagon-like peptide-1 receptor agonist that improves glycemic control primarily by stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, and reducing appetite, which can lead to weight loss. **Insulin glargine** is a long-acting basal insulin analog that lowers blood glucose by enhancing peripheral glucose uptake and inhibiting hepatic glucose production. When used together, this combination may provide superior control of blood glucose and body weight compared to either agent alone. The combination is administered via subcutaneous injection. There is evidence from clinical trials and meta-analyses supporting the efficacy and safety of this combination, particularly in individuals with inadequately controlled type 2 diabetes. However, the combined use increases the risk of hypoglycemia and may lead to more gastrointestinal side effects such as nausea, vomiting, and diarrhea, mainly attributed to semaglutide[5][9].